Learn more about our new NGS
Sarcoma Fusion Profiles and more

Join us at CAP16

Join us at CAP16

September 25-28, Booth 500 | Wynn/Encore, Las Vegas
September 25-28, Booth 500 | Wynn/Encore, Las Vegas
September 25-28, Booth 500 | Wynn/Encore, Las Vegas

Bring Clarity to
a complex disease

Advanced Technologies to better characterize
and assess cancer

GE Healthcare Biopharma Services

Pharma Services

NeoGenomics offers lab services for oncology clinical trials

Learn more 
Clarient

Clarient Client Resources

For current Clarient clients only, access your Clarient resources here.

Browse Resources

News

Image%20Alt%20Text

PD-L1 Updates

SP142 for bladder cancer now available

Learn more

American Society of Human Genetics

Visit Us at Booth 533

Image%20Alt%20Text

HER-2 Breast FISH Alternative Assessment

The July-December 2016 self-assessment for our tech-only FISH clients is ready.

Sign into NeoUniversity™

Modern Diagnosis of Sarcoma

Presented by

Lawrence M. Weiss, MD, Medical Director for NeoGenomics/Clarient and Tony Tran, BS

Published Tuesday, September 27, 2016

View webinar

New Tests

Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.

Indicated as an aid in identifying patients most likely to benefit from TECENTRIQ®

PD-L1, 142 (FDA) TECENTRIQ®

Learn more

Comprehensive detection of sarcoma translocations by next-gen sequencing to enhance diagnosis, subclassification, and treatment

Learn more

NGS Comprehensive Sarcoma
Fusion Profile

Targeted next-gen sequencing panel that detects significant translocations in the genes NTRK1, NTRK3, and RET

Learn more

NGS Thyroid Fusion Profile

Comprehensive detection of sarcoma transocations by next-gen sequencing to enhance diagnosis, subclassification, and treatment

Learn more

NGS Comprehensive Sarcoma
Fusion Profile